1-3 of 3
Peter Westervelt, M.D., Ph.D.
Close
Sort by
Journal Articles

Tolerability of PTK787/ZK 222584 in a Phase II Study of Post-Transplant Maintenance Therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem Cell Transplant.

James C. Mosley, III, MD, Shachar Peles, M.D., Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Camille Abboud, M.D., Amanda Cashen, M.D., Geoffrey Uy, M.D., Peter Westervelt, M.D., Ph.D., John F. DiPersio, M. D., Ph.D., Ravi Vij, M.D.
Journal: Blood
Blood (2007) 110 (11): 5109.
https://doi.org/10.1182/blood.V110.11.5109.5109
Published: 2007
Journal Articles

The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.

Tanya M. Wildes, MD, Alisa Ruddell, B.A., Feng Gao, M.D., Ph.D., Geoffrey Uy, M.D., Amanda Cashen, M.D., Camille Abboud, M.D., Peter Westervelt, M.D., Ph.D., John F. Dipersio, M.D., Ph.D., Ravi Vij, M.D.
Journal: Blood
Blood (2007) 110 (11): 1182.
https://doi.org/10.1182/blood.V110.11.1182.1182
Published: 2007
Journal Articles

Salvage Therapy with Flag/Idarubicin/Mylotarg (Flag-IM) Results in a Superior CR/CRp Rate and Low Toxicity When Compared to Mitoxantrone/Etoposide/Cytarabine (MEC) in Patients with Relapsed and Refractory AML.

Brian A. Van Tine, MD, PhD, Kristan M. Augustin, Ph.D., David I. Kuperman, M.D., Bruno Nervi, M.D., Peter Westervelt, M.D./Ph.D., John F. DiPersio, M.D./Ph.D.
Journal: Blood
Blood (2006) 108 (11): 4576.
https://doi.org/10.1182/blood.V108.11.4576.4576
Published: 2006